Coma After Greater Occipital Nerve Blockade in a Patient With Previous Posterior Fossa Surgery
- Conflicts of Interest: TS has consulted for Eli Lilly, Allergan, Mitsubishi Pharma, Genzyme, and Biogen Idec. He received reimbursement for travel expenses or lectures from Janssen, Pfizer, Bayer Schering, Eli Lilly, and Biogen. CLS has nothing to declare.
Address all correspondence to T. Sprenger, Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
We here report the case of a patient who previously underwent posterior fossa surgery and was later treated with greater occipital nerve blockade for unilateral facial pain. The patient went into coma immediately post-injection but made a full recovery without sequelae after intensive care treatment. Physicians should be aware of the risks of greater occipital nerve blockade after previous posterior fossa craniotomy.